| Autor: |
Brand LM; Procter & Gamble Company, Cincinnati, OH 45239., Skare KL, Loomans ME, Reller HH, Schwen RJ, Lade DA, Bohne RL, Maddin CS, Moorehead DP, Fanelli R, et. al. |
| Jazyk: |
angličtina |
| Zdroj: |
Agents and actions [Agents Actions] 1990 Nov; Vol. 31 (3-4), pp. 329-40. |
| DOI: |
10.1007/BF01997628 |
| Abstrakt: |
We have evaluated the properties of a new class of anti-inflammatory agents derived from capsaicin, using the analogs NE-19550 (N-vanillyloleamide) and NE-28345 (N-oleyl-homovanillamide) as examples. This class displayed an atypical profile in the assays utilized, including 1) anti-edema and antileukocyte migration activity in the rat carrageenan pleurisy assay without suppression of pleural prostanoid synthesis, 2) blockade of human platelet aggregation induced by arachidonate or PAF but not that induced by the PGH2 analog U-46619, without equivalent inhibition in vitro of mammalian cyclooxygenase or thromboxane synthetase preparations, 3) greater potency and efficacy in the rat implanted sponge assay than in the adjuvant arthritis assay, without inhibition of LTB4 or 15-HETE synthesis in vitro, 4) stronger topical activity in the mouse croton oil inflamed ear assay than the guinea pig UV erythema assay, and 5) oral activity in the rat carrageenan paw edema assay and mouse phenylquinone abdominal constriction rest combined with failure to induce gastric erosion in rats at therapeutic doses. We conclude that NE-19550 and NE-28345 do not act like conventional NSAIDs via suppression of arachidonic acid metabolism. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
